DYRK1B seems to be particularly tightly interwoven with this pathway as several points of interaction exist: (i) DYRK1B overexpression promotes mTOR activation and combined inhibition of DYRK1B and mTOR has superior impact on pancreatic and ovarian cancer cell growth compared to single treatment [67, 73, 94, 100]. Here, MTOR is linked to ovarian cancer.